SNRNP200 and neoplasm: Compared with the LDH inhibitor FX-11 plus anti-PD-1, co-administration of ASO-Snrnp200 and anti-PD-1 markedly inhibited tumor growth (Fig. 7d and Supplementary Fig. S11d, e).